Revium Rx (RVRC) Cash & Equivalents (2024 - 2025)
Revium Rx recorded quarterly Cash & Equivalents of $1.7 million in Q4 2025, down 48.65% quarter-over-quarter from $3.3 million in Q4 2024, and down 48.65% year-over-year from $3.3 million in Q4 2024.
Revium Rx's Cash & Equivalents history runs 2 years deep, the most recent figure standing at $1.7 million for Q4 2025.
- In Q4 2025, Cash & Equivalents fell 48.65% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (down 48.65% YoY), while the FY2025 annual figure was $1.7 million, down 48.65% from the prior year.
- Cash & Equivalents came in at $1.7 million for Q4 2025 at Revium Rx, down from $3.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $3.3 million in Q4 2024 to a low of $1.7 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | 1.42 Bn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | 888.80 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | 265.37 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | 186.67 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | 219.18 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | 34.34 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | 490.29 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | 419.52 Mn |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | 174.90 Mn |
| 10 | Revium Rx | - | - | - | 1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.68 Mn |
| Dec 31, 2024 | 3.27 Mn |